Furthermore, the simultaneous inhibition of CCR1 and CXCR2 expressed on myeloid cells can result in more robust suppression of tumor growth and metastasis, highlighting the potential of combinational therapeutic strategies targeting multiple chemokine receptors [30]. This evidence concerns the gene CXCR2 and neoplasm.